← Back to Search

Monoclonal Antibodies

AL002 for Alzheimer's Disease

Phase 2
Recruiting
Led By TBD TBD
Research Sponsored by Alector Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to 49 weeks
Awards & highlights

Study Summary

This trial evaluates how safe, tolerable and effective a new Alzheimer's treatment is over time.

Who is the study for?
This trial is for individuals with Early Alzheimer's Disease who completed the AL002-2 study, can consent to participate, and have a caregiver involved at least 10 hours weekly. Those unable to consent or discontinued from the previous study due to safety cannot join.Check my eligibility
What is being tested?
The trial is testing the long-term effects of a drug called AL002 on safety, tolerability, and effectiveness in treating Early Alzheimer's Disease. It extends prior research by continuing treatment with this drug.See study design
What are the potential side effects?
Specific side effects are not listed here but generally include any adverse reactions observed during the ongoing treatment with AL002. These could range from mild symptoms to more serious health concerns.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to 49 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 49 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability as measured by number of/incidence of Adverse Events (AEs), including AESI and SAEs.
Safety and tolerability as measured by the number of incidence/MRI abnormalities.

Trial Design

3Treatment groups
Experimental Treatment
Group I: AL002 Dose 3Experimental Treatment1 Intervention
AL002 every 4 weeks
Group II: AL002 Dose 2Experimental Treatment1 Intervention
AL002 every 4 weeks
Group III: AL002 Dose 1Experimental Treatment1 Intervention
AL002 every 4 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AL002
2018
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

Alector Inc.Lead Sponsor
10 Previous Clinical Trials
1,075 Total Patients Enrolled
AbbVieIndustry Sponsor
958 Previous Clinical Trials
502,180 Total Patients Enrolled
TBD TBDPrincipal Investigator
6 Previous Clinical Trials
1,414 Total Patients Enrolled

Media Library

AL002 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05744401 — Phase 2
Alzheimer's Disease Research Study Groups: AL002 Dose 1, AL002 Dose 2, AL002 Dose 3
Alzheimer's Disease Clinical Trial 2023: AL002 Highlights & Side Effects. Trial Name: NCT05744401 — Phase 2
AL002 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05744401 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being accepted for enrollment in this study?

"The study, which was initially posted on April 1st 2023 and subsequently edited on February 15th of the same year, is currently in need of participants. This information can be found documented on clinicaltrials.gov."

Answered by AI

Does this clinical trial accept participants aged 70 and above?

"Meeting the stipulated criteria for inclusion, the bottom limit of age to be allowed in this research project is 50 and its upper end stands at 85."

Answered by AI

How hazardous is AL002 Dose 1 to human health?

"Given that this is an exploratory Phase 2 trial, AL002 Dose 1 was adjudged to have a safety rating of 2. This score reflects the presence of some data regarding its security but none confirming efficacy."

Answered by AI

Do I possess the necessary qualifications to enroll in this investigation?

"This trial seeks patients with Alzheimer's disease between the ages of fifty and eighty-five. Approximately 190 participants are needed to meet enrollment goals."

Answered by AI

What is the cap on the amount of people participating in this trial?

"To progress this clinical trial, 190 volunteers that meet the inclusion criteria must partake. These individuals can apply at Advanced Clinical Institute in Neptune (NJ) or Summit Research Network in Portland (OR)."

Answered by AI

Who else is applying?

What site did they apply to?
Advanced Clinical Institute
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
2023. "A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05744401.
All > Alzheimers Disease New York
~108 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top